Metoject® PEN
Methotrexate 50 mg/ml
Therapeutic Indication:
Metoject® PEN is indicated for the treatment of:
- Active rheumatoid arthritis in adult patients.
- Polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate.
- Moderate to severe psoriasis in adult patients who are candidates for systemic therapy, and severe psoriatic arthritis in adults.
- Mild to moderate Crohn’s disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.
- Composition: Methotrexate 50 mg/ml.
- Pharmaceutical Form: Solution for Injection.
- Method of Administration: Subcutaneous.
- How Supplied: Prefilled Syringe/Pen.
- Manufacturer: Medac GmbH, Germany.